Panagiotis Garantziotis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Panagiotis Garantziotis has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- George Bertsias
Rheumatology, Clinical Immunology, Medical School, University of Crete, Heraklion, Greece
4 shared publications - Dimitrios T. Boumpas
Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece
3 shared publications Spyridon Katechis
4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
3 shared publicationsAnastasia Filia
Laboratory of Autoimmunity and Inflammation, Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation Academy of Athens, Athens, Greece
2 shared publications- Antigone Pieta
4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
2 shared publications Antonis Fanouriakis
4th Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
2 shared publications
Latest Publications
- Open Access
A Feed-Forward Loop Between Extrafollicular B Cell Differentiation and the Inflammatory Milieu Governs Remission and Relapse in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is driven by pathogenic B cells. Yet, why some patients receiving B cell depletion achieve durable remission, whilst others fail remains unclear. Here we use CD19-directed chimeric antigen receptor (CAR) T cell therapy as a mechanistic probe in 18 patients with refractory SLE 1,2 , with longitudinal follow-up extending up to 40 months. We show that durable, drug-free remission is defined not by the depth of B cell depletion alone, but by the elimination of the extrafollicular (EF) B cell differentiation trajectory – specifically, activated naïve B cell precursors and CD11c + T-bet + double-negative type 2 B cells. In long-term responders, B cell reconstitution recapitulated healthy ontogeny, while the EF pathway remained truncated, coinciding with collapse of the interferon-rich milieu and contraction of PD1 hi T peripheral helper cells. In contrast, in relapse, persistently elevated CXCL13, interferons and expanded PD1 hi T cells preceded the B cell return, and nascent B cells immediately followed the EF differentiation trajectory in the confirmed absence of germinal centers in the lymph node, shortly followed by clinical symptoms. These findings indicate that CAR-T cell therapy achieves remission by breaking a feed-forward loop between the systemic inflammatory environment and extrafollicular B cell differentiation.
Open AccessA Feed-Forward Loop Between Extrafollicular B Cell Differentiation and the Inflammatory Milieu Governs Remission and Relapse in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is driven by pathogenic B cells. Yet, why some patients receiving B cell depletion achieve durable remission, whilst others fail remains unclear. Here we use CD19-directed chimeric antigen receptor (CAR) T cell therapy as a mechanistic probe in 18 patients with refractory SLE 1,2 , with longitudinal follow-up extending up to 40 months. We show that durable, drug-free remission is defined not by the depth of B cell depletion alone, but by the elimination of the extrafollicular (EF) B cell differentiation trajectory – specifically, activated naïve B cell precursors and CD11c + T-bet + double-negative type 2 B cells. In long-term responders, B cell reconstitution recapitulated healthy ontogeny, while the EF pathway remained truncated, coinciding with collapse of the interferon-rich milieu and contraction of PD1 hi T peripheral helper cells. In contrast, in relapse, persistently elevated CXCL13, interferons and expanded PD1 hi T cells preceded the B cell return, and nascent B cells immediately followed the EF differentiation trajectory in the confirmed absence of germinal centers in the lymph node, shortly followed by clinical symptoms. These findings indicate that CAR-T cell therapy achieves remission by breaking a feed-forward loop between the systemic inflammatory environment and extrafollicular B cell differentiation.
- 27 April 2026
- Published by OAE Publishing Inc. in Rare Disease and Orphan Drugs Journal
- Vol. 5 (2)
Applications and prospects of machine learning in the diagnosis and treatment of SLE
Systemic lupus erythematosus (SLE) remains a major clinical challenge due to its broad phenotypic variability, unpredictable disease trajectory, and inconsistent therapeutic responses. The limitations of conventional diagnostic and prognostic tools underscore the need for more precise, data-driven approaches to support clinical decision-making. Artificial intelligence-based methods, including machine learning (ML) have emerged as powerful technologies capable of analyzing complex, high-dimensional data to reveal hidden patterns and enhance disease understanding. These methods are particularly well-suited for tackling the multifactorial nature of SLE and have demonstrated utility in improving diagnostic accuracy, classifying disease subtypes, and guiding personalized treatment strategies. This review offers a clinician-oriented overview of foundational ML approaches and their practical applications in SLE, highlighting how these tools might be incorporated into clinical workflows to support more timely, accurate, and individualized care.
- 27 April 2026
- Published by OAE Publishing Inc. in Rare Disease and Orphan Drugs Journal
- Vol. 5 (2)
Applications and prospects of machine learning in the diagnosis and treatment of SLE
Systemic lupus erythematosus (SLE) remains a major clinical challenge due to its broad phenotypic variability, unpredictable disease trajectory, and inconsistent therapeutic responses. The limitations of conventional diagnostic and prognostic tools underscore the need for more precise, data-driven approaches to support clinical decision-making. Artificial intelligence-based methods, including machine learning (ML) have emerged as powerful technologies capable of analyzing complex, high-dimensional data to reveal hidden patterns and enhance disease understanding. These methods are particularly well-suited for tackling the multifactorial nature of SLE and have demonstrated utility in improving diagnostic accuracy, classifying disease subtypes, and guiding personalized treatment strategies. This review offers a clinician-oriented overview of foundational ML approaches and their practical applications in SLE, highlighting how these tools might be incorporated into clinical workflows to support more timely, accurate, and individualized care.
- Open Access
- 21 January 2026
- Published by Elsevier in Journal of Autoimmunity
- Vol. 159, 103525
Molecular stratification and transcriptome-guided therapeutics in systemic lupus erythematosus with insufficient treatment response
- 21 January 2026
- Published by Elsevier in Journal of Autoimmunity
- Vol. 159, 103525
Open AccessMolecular stratification and transcriptome-guided therapeutics in systemic lupus erythematosus with insufficient treatment response
- Open Access
Systemic lupus erythematosus damage risk index (SLE-DRI): a simple machine learning-based tool for identifying patients at risk for early organ damage
Objective: Organ damage is a key determinant of poor prognosis and increased mortality in systemic lupus erythematosus (SLE). However, no validated clinical tools for predicting damage accumulation currently exist. We sought to develop a machine learning-based model to predict early organ damage in patients with SLE. Methods: Classification criteria (American College of Rheumatology (ACR)-1997, Systemic Lupus International Collaborating Clinics (SLICC)-2012, European League Against Rheumatism (EULAR)/ACR-2019) and non-criteria features of a cohort of 914 patients with SLE were analysed to predict damage (defined as SLICC/ACR Damage Index (SDI)) within 5 years since diagnosis. Feature selection and model construction were performed using the least absolute shrinkage and selection operator-logistic regression (LASSO-LR). The best model in 10-fold cross-validation was tested in an external cohort (n=50). Results: A LASSO-LR model incorporating 16 criteria and non-criteria features predicted early organ damage with area under the receiver operating characteristic curve (AUC) values of 0.80 (95% CI 0.74 to 0.87) and 0.86 (95% CI 0.76 to 0.97) in the derivation and external validation cohorts, respectively, outperforming the ACR-1997 (AUC 0.70; 95% CI 0.62 to 0.78), SLICC-2012 (AUC 0.74; 95% CI 0.66 to 0.81) and EULAR/ACR-2019 (AUC 0.70; 95% CI 0.63 to 0.78) classification systems. Features most strongly associated with damage included the SLICC-2012 neurological disorder, EULAR/ACR-2019 class III/IV lupus nephritis and among non-criteria manifestations, myocarditis and interstitial lung disease. Operating the model as a binary classifier (early damage versus no damage), it demonstrated high specificity (0.90, 95% CI 0.78 to 0.95). The model can be converted to a simplified scoring system, with a threshold of ≥3 achieving an AUC of 0.86 (95% CI 0.75 to 0.96). Conclusion: We developed and validated a clinician-friendly model for early organ damage prediction in SLE, facilitating risk stratification.
Open AccessSystemic lupus erythematosus damage risk index (SLE-DRI): a simple machine learning-based tool for identifying patients at risk for early organ damage
Objective: Organ damage is a key determinant of poor prognosis and increased mortality in systemic lupus erythematosus (SLE). However, no validated clinical tools for predicting damage accumulation currently exist. We sought to develop a machine learning-based model to predict early organ damage in patients with SLE. Methods: Classification criteria (American College of Rheumatology (ACR)-1997, Systemic Lupus International Collaborating Clinics (SLICC)-2012, European League Against Rheumatism (EULAR)/ACR-2019) and non-criteria features of a cohort of 914 patients with SLE were analysed to predict damage (defined as SLICC/ACR Damage Index (SDI)) within 5 years since diagnosis. Feature selection and model construction were performed using the least absolute shrinkage and selection operator-logistic regression (LASSO-LR). The best model in 10-fold cross-validation was tested in an external cohort (n=50). Results: A LASSO-LR model incorporating 16 criteria and non-criteria features predicted early organ damage with area under the receiver operating characteristic curve (AUC) values of 0.80 (95% CI 0.74 to 0.87) and 0.86 (95% CI 0.76 to 0.97) in the derivation and external validation cohorts, respectively, outperforming the ACR-1997 (AUC 0.70; 95% CI 0.62 to 0.78), SLICC-2012 (AUC 0.74; 95% CI 0.66 to 0.81) and EULAR/ACR-2019 (AUC 0.70; 95% CI 0.63 to 0.78) classification systems. Features most strongly associated with damage included the SLICC-2012 neurological disorder, EULAR/ACR-2019 class III/IV lupus nephritis and among non-criteria manifestations, myocarditis and interstitial lung disease. Operating the model as a binary classifier (early damage versus no damage), it demonstrated high specificity (0.90, 95% CI 0.78 to 0.95). The model can be converted to a simplified scoring system, with a threshold of ≥3 achieving an AUC of 0.86 (95% CI 0.75 to 0.96). Conclusion: We developed and validated a clinician-friendly model for early organ damage prediction in SLE, facilitating risk stratification.
- Open Access
- 9 May 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (8) , 1342-1353
Enhanced B cell and complement cascade gene signatures in patients with neuropsychiatric systemic lupus erythematosus
- 9 May 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (8) , 1342-1353
Open AccessEnhanced B cell and complement cascade gene signatures in patients with neuropsychiatric systemic lupus erythematosus
- Open Access
Transcriptome analysis to decipher the molecular underpinnings of response to treatment in systemic lupus erythematosus
Objective Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterised by variable treatment responses. We investigated the transcriptional landscape associated with treatment response and resistance in SLE. Methods Blood was collected from 92 active patients with SLE at baseline and after 6 months (n=32 paired samples) of treatment with cyclophosphamide (n=40), rituximab (n=20), belimumab (n=23), mycophenolate mofetil (n=8) or azathioprine (n=1) and was subjected to RNA sequencing. The response was defined by the Lupus Low Disease Activity State. We identified differentially expressed genes and co-expressed transcript modules. Results Achieving response, irrespective of treatment, was accompanied by downregulation of B cell immunity-related and complement activation-related signatures. Rituximab led to the most profound decrease in the activity of the B cell pathway, while cyclophosphamide uniquely downregulated neutrophil activation pathways. Responders, regardless of medication, showed increased activity in pathways related to neutrophil migration, type I interferon signalling, complement activation and B cell function prior to treatment. A 539-gene signature, enriched in processes related to chemokine signalling, characterised patients with insufficient response to treatment. Conclusions Baseline B cell immunity transcriptional signatures correlate with favourable treatment outcomes—accounting for better responses in serologically active patients in SLE clinical trials—with effective treatment reversing the B cell immunity signature. Cyclophosphamide uniquely targets a neutrophil gene signature linked to severe SLE. Alterations in chemotaxis may represent a mechanism driving resistance to treatment in SLE.
Open AccessTranscriptome analysis to decipher the molecular underpinnings of response to treatment in systemic lupus erythematosus
Objective Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterised by variable treatment responses. We investigated the transcriptional landscape associated with treatment response and resistance in SLE. Methods Blood was collected from 92 active patients with SLE at baseline and after 6 months (n=32 paired samples) of treatment with cyclophosphamide (n=40), rituximab (n=20), belimumab (n=23), mycophenolate mofetil (n=8) or azathioprine (n=1) and was subjected to RNA sequencing. The response was defined by the Lupus Low Disease Activity State. We identified differentially expressed genes and co-expressed transcript modules. Results Achieving response, irrespective of treatment, was accompanied by downregulation of B cell immunity-related and complement activation-related signatures. Rituximab led to the most profound decrease in the activity of the B cell pathway, while cyclophosphamide uniquely downregulated neutrophil activation pathways. Responders, regardless of medication, showed increased activity in pathways related to neutrophil migration, type I interferon signalling, complement activation and B cell function prior to treatment. A 539-gene signature, enriched in processes related to chemokine signalling, characterised patients with insufficient response to treatment. Conclusions Baseline B cell immunity transcriptional signatures correlate with favourable treatment outcomes—accounting for better responses in serologically active patients in SLE clinical trials—with effective treatment reversing the B cell immunity signature. Cyclophosphamide uniquely targets a neutrophil gene signature linked to severe SLE. Alterations in chemotaxis may represent a mechanism driving resistance to treatment in SLE.